GlassScriptPhysician profile
Prasad V Reddy
NPI 1588862262
$6,977.30
in general payments reported to CMS, 2019-2025
23 companies · $1,450 in 2025
The $1,450 reported for 2025 was more than what 86% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $449 · 2020: $346 · 2021: $955 · 2022: $1,060 · 2023: $1,268 · 2024: $1,450 · 2025: $1,450.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,852 · Education: $316.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,852.01 |
| Education | $315.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $1,318.34 | 2019-2025 | Aristada, Lybalvi, Aristada Initio |
| Teva Pharmaceuticals USA, INC. | $1,165.14 | 2022-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Supernus Pharmaceuticals, INC. | $765.06 | 2021-2025 | Qelbree, Qelbree |
| Abbvie INC. | $603.58 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $472.39 | 2020-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $392.18 | 2019-2022 | |
| Ironshore Pharmaceuticals INC. | $348.66 | 2019-2024 | Jornay Pm |
| Lundbeck LLC | $303.26 | 2019-2024 | Rexulti |
| Janssen Pharmaceuticals, INC | $288.81 | 2019-2024 | Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $269.82 | 2020-2025 | Caplyta |
| Axsome Therapeutics, INC. | $260.76 | 2023-2025 | Auvelity |
| Neurocrine Biosciences, INC. | $157.34 | 2020-2025 | Ingrezza |
| Indivior INC. | $112.74 | 2019-2024 | Perseris |
| Corium, LLC | $102.98 | 2022-2024 | Azstarys |
| E.R. Squibb & Sons, L.L.C. | $99.65 | 2024-2025 | Cobenfy |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $65.68 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $58.11 | 2024-2025 | Fanapt, Hetlioz |
| Owp Pharmaceuticals, INC. | $46.75 | 2023 | Lamotrigine, Subvenite |
| Collegium Pharmaceutical, INC. | $41.89 | 2025 | Jornay Pm |
| Avanir Pharmaceuticals, INC. | $40.41 | 2019-2022 | |
| Idorsia Pharmaceuticals US INC | $30.66 | 2023 | Quviviq |
| Merck Sharp & Dohme LLC | $19.38 | 2020 | |
| Eisai INC. | $13.71 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Prasad Reddy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.